The effects and side effects of Cinnarizine and Bethahistine in The Treatment of Patients with Acute Peripheral Vertigo
Phase 3
- Conditions
- Benign Positional Vertigo.Benign paroxysmal Positional vertigo
- Registration Number
- IRCT20130710013947N9
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Age more than 18 years old
Age less than 60 years old
patients referred with Benign Positional Vertigo (BPV)
Did not use drug before reference
Exclusion Criteria
Meniere syndrome
Vertigo caused by untreated primary organ disease
Pregnancy
Patients use Benzodiazepines, CNS suppressant, Barbiturates
History of internal and middle ear surgery
Migraine headaches
Headache at the time of study
A history of mental or neurological illness
Gastric ulcer and digestive problems
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of positional vertigo. Timepoint: At first, 3rd days and 1 week later. Method of measurement: Visual Analog Scale.
- Secondary Outcome Measures
Name Time Method Significance improvement. Timepoint: 3rd days and 1 week later after treatment. Method of measurement: Mean Vertigo Score (MVS).